logo

TMDX

TransMedics Group·NASDAQ
--
--(--)
--
--(--)
8.50 / 10
Outperform

The fundamental framework scores 8.5/10 - strong quality. Supporting factors: Net profit attributable to parent company shareholders (YoY growth rate %) and Quick ratio, although drawbacks are visible in Net cash flow from operating activities (YoY growth rate %). Overall perspective: highly favorable.

Fundamental(8.5)SentimentTechnical

Analysis Checks(9/10)

Total operating revenue (YoY growth rate %)
Value39.01
Score3/3
Weight15.49%
1M Return4.49%
Quick ratio
Value7.13
Score3/3
Weight27.68%
1M Return9.20%
Total profit (YoY growth rate %)
Value198.32
Score3/3
Weight14.27%
1M Return5.05%
Net cash flow from operating activities (YoY growth rate %)
Value443.33
Score1/3
Weight-5.64%
1M Return-2.87%
Fixed assets turnover ratio
Value1.48
Score3/3
Weight11.66%
1M Return4.11%
Long-term debt to working capital ratio (%)
Value0.96
Score3/3
Weight14.62%
1M Return5.10%
Interest coverage ratio (EBIT / Interest expense) (%)
Value61.44
Score2/3
Weight-4.23%
1M Return-1.71%
Operating revenue (YoY growth rate %)
Value39.01
Score3/3
Weight15.49%
1M Return4.49%
Net profit attributable to parent company shareholders (YoY growth rate %)
Value196.81
Score3/3
Weight11.04%
1M Return3.96%
Inventory turnover days
Value70.11
Score3/3
Weight-0.38%
1M Return-0.14%
Is TMDX undervalued or overvalued?
  • TMDX scores 8.50/10 on fundamentals and holds a Discounted valuation at present. Backed by its 29.09% ROE, 16.20% net margin, 50.30 P/E ratio, 12.99 P/B ratio, and 176.53% earnings growth, these metrics solidify its Outperform investment rating.